You are Trying to View a Free Article

Daily News You Can't Find Anywhere Else

Gilead Bolsters Cancer Portfolio with $21 Billion Immunomedics Buy, an Industrial Info Market Brief

default

Industry Segment: Market Brief | Word Count: 146 Words
Attachment: Map

While the quest for a COVID-19 vaccine garners the most attention in the news, there are obviously a plethora of other conditions that require treatment. Near the top of desired therapeutics are oncology (cancer) drugs. Biotech Gilead recently signed a $21 billion deal to purchase breast cancer drug developer Immunomedics Incorporated.

Subscribe Now! All Fields Required...

Standard Membership - Free